Alnylam Pharmaceuticals Stock Sees Healthy Rising Relative Strength Rating

The Relative Strength (RS) Rating for Alnylam Pharmaceuticals (ALNY) climbed into a new percentile Monday, as it got a lift from 63 to 71.


When you’re researching the best stocks to buy and watch, keep a close on eye on relative price strength.

This proprietary rating measures market leadership by showing how a stock’s price action over the last 52 weeks compares to that of the other stocks in our database.

Decades of market research reveals that the best stocks typically have an RS Rating of over 80 in the early stages of their moves. See if Alnylam Pharmaceuticals can continue to show renewed price strength and clear that threshold.

Looking For The Best Stocks To Buy And Watch? Start Here

Is Alnylam Pharmaceuticals Stock A Buy?

Alnylam Pharmaceuticals stock broke out earlier, but has fallen back below the prior 177.63 entry from a cup with handle. It’s still trading just below the buy point so keep an eye on the stock to see if it moves higher on strong volume or if the stock creates a new pattern. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips.


Alnylam Pharmaceuticals stock showed -7% earnings growth last quarter, while sales growth came in at 78%. Look for the next report on or around Aug. 6.

The biotech firm holds the No. 51 rank among its peers in the Medical-Biomed/Biotech industry group. Regeneron Pharmaceutical (REGN) and Avid Bioservices (CDMO) are also among the group’s highest-rated stocks. For more industry news, check out “Biotech And Pharmaceutical Industry And Stock News.”


MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks


Most Related Links :
reporterwings Governmental News Finance News

Source link

Back to top button